Differing NAD+ kinase roles in melanoma spread
Official title: Differential role of different NAD+ kinase Isoforms in melanoma metastasis-Relinquishment
Funded at Beth Israel Deaconess Medical Center · NIH-11408660 · Data updated 2026-11-12
Researchers are studying how different NAD+ kinase forms affect the spread of melanoma, with the goal of finding new angles to prevent metastasis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $395,509 |
| NIH project number | 5R01CA270885-06 |
| Project ID | NIH-11408660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals with melanoma whose tumors can be modeled with patient-derived xenografts or who have metastatic disease suitable for research collaboration.
✕Less likely to help
Patients without access to tumor samples or who are not eligible for related translational studies may not directly benefit.
What this research studies
This project follows melanoma from a patient-derived model to understand how cells spread and survive in new sites. It uses models that better reflect human tumors and focuses on metabolic changes involving NADP+/NADPH during metastasis. If successful, it could reveal new targets to stop cancer cells from colonizing distant tissues and help guide future therapies for metastatic melanoma.
Why it matters
Potential benefit: If successful, the work could identify new targets to prevent or limit melanoma metastasis, potentially helping patients live longer.
How similar studies have gone: Previous work with patient-derived melanoma models suggests metabolic adaptations support metastasis, indicating this approach has merit but remains complex.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Piskounova, Elena — Beth Israel Deaconess Medical Center
- Study coordinator: Piskounova, Elena
Related research
Other NIH-funded projects on the same topics.
-
Understanding how palmitoylation affects Cadherin-Catenin cell adhesion and lung melanoma spread
This NIH grant studies how a chemical modification called palmitoylation influences how melanoma cells stick together and spread to the lungs, with potential to improve future treatments.
-
Role of GTP supply and localization in melanoma invasion and brain metastasis
This project looks at how the cell’s energy and building blocks for RNA and DNA help melanoma cells invade and spread to the brain.
-
Melanoma spread and therapy resistance in aging: decoding stress signals and gut microbes
This project aims to understand how aging changes melanoma's response to treatment by studying key stress signals inside tumors and the gut bacteria that shape anti-tumor immunity.
-
Preventing Melanoma Spread by Targeting Lipid Weaknesses in Lymph
Aims to block early melanoma metastasis by disrupting how cancer cells use fats in the lymphatic system.
-
GAPDHS and melanoma metabolism: a new biomarker and target
A researcher is studying how a brain/germ cell enzyme GAPDHS affects melanoma cancer metabolism and the cancer’s ability to spread, with the aim of finding biomarkers and new ways to predict or limit metastasis.
-
Epigenetic regulators shaping melanoma cell diversity and spread
A study at NYU School of Medicine looks at how changes in gene regulation inside melanoma cells might drive varied cell states and help cancer spread.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.